Dong, Yanling
Wang, Shuang
Cong, Lin
Zhang, Ting
Cheng, Jun
Yang, Nannan
Qu, Xiaohong
Li, Dongfang
Zhou, Xueying
Wang, Holly
Lee, Michael
Wang, Meng
Chen, Stephen http://orcid.org/0000-0001-6967-0254
Ousler, George W.
Chen, Xiaoxiang
Xie, Lixin
Clinical trials referenced in this document:
Documents that mention this clinical trial
TNF-α inhibitor tanfanercept (HBM9036) improves signs and symptoms of dry eye in a phase 2 trial in the controlled adverse environment in China
https://doi.org/10.1007/s10792-022-02245-1
Funding for this research was provided by:
Harbour BioMed
Article History
Received: 28 October 2021
Accepted: 10 February 2022
First Online: 22 February 2022
Declarations
:
: All authors declare that they have no conflict of interest.
: Informed consent was obtained from each subject before any study-specific procedures were performed.
: This study was approved by Institutional Ethics Committee (IEC) for Drugs/Medical Devices Clinical Trials, Qingdao Eye Hospital of Shandong First Medical University.